Obsidian Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | After market close | – | – | – |
Press releases
Announcements Obsidian Therapeutics filed with the SEC
Obsidian Therapeutics Completes Closing of Transaction with Galera
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
should carefully consider the following risk factors. These risk factors are not exhaustive, and investors are encouraged to perform their own investigation with respect to the businesses of Obsidian. The occurrence of one or more of the events or
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
requires, references in this section to “we,” “us,” “our” and the “Company” refer to Obsidian.
Material agreement · Acquisition or disposition completed · Results of operations · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K